共 49 条
- [44] Use of G-CSF in patients with severe aplastic anaemia treated with ATG and cyclosporine increases neutrophils and decreases infection rates and hospitalization days but does not improve long-term outcome: Results of a prospective randomized clinical trial BONE MARROW TRANSPLANTATION, 2010, 45 : S31 - S31
- [45] The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2024, 16
- [46] Use of G-CSF in Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine Increases Neutrophils and Decreases Infection Rates and Hospitalization Days but Does Not Improve Long-Term Outcome: Results of a Prospective, Randomized Clinical Trial of the EBMT. BLOOD, 2009, 114 (22) : 205 - 205
- [47] Efficacy and safety of early target-controlled plasma volume replacement with a balanced gelatine solution versus a balanced electrolyte solution in patients with severe sepsis/septic shock: study protocol, design, and rationale of a prospective, randomized, controlled, double-blind, multicentric, international clinical trial: GENIUS-Gelatine use in ICU and sepsis TRIALS, 2021, 22 (01)
- [48] Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized, Uncontrolled, and Investigator-Initiated Clinical Trial Cardiovascular Drugs and Therapy, 2018, 32 : 373 - 379
- [49] Assessment of Safety and Effectiveness of the Extracorporeal Continuous-Flow Ventricular Assist Device (BR16010) Use as a Bridge-to-Decision Therapy for Severe Heart Failure or Refractory Cardiogenic Shock: Study Protocol for Single-Arm Non-randomized, Uncontrolled, and Investigator-Initiated Clinical Trial CARDIOVASCULAR DRUGS AND THERAPY, 2018, 32 (04) : 373 - 379